Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Position Boosted by Velan Capital Investment Management LP

Velan Capital Investment Management LP lifted its holdings in shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) by 50.0% in the fourth quarter, Holdings Channel.com reports. The fund owned 300,000 shares of the company’s stock after purchasing an additional 100,000 shares during the period. Zevra Therapeutics comprises approximately 2.2% of Velan Capital Investment Management LP’s portfolio, making the stock its 9th largest holding. Velan Capital Investment Management LP’s holdings in Zevra Therapeutics were worth $2,502,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Barclays PLC boosted its position in Zevra Therapeutics by 292.6% during the 3rd quarter. Barclays PLC now owns 57,599 shares of the company’s stock valued at $399,000 after acquiring an additional 42,926 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its position in shares of Zevra Therapeutics by 51.2% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 20,565 shares of the company’s stock valued at $172,000 after purchasing an additional 6,966 shares in the last quarter. JPMorgan Chase & Co. boosted its position in shares of Zevra Therapeutics by 50.5% during the fourth quarter. JPMorgan Chase & Co. now owns 27,490 shares of the company’s stock valued at $229,000 after purchasing an additional 9,225 shares in the last quarter. Raymond James Financial Inc. purchased a new stake in Zevra Therapeutics in the fourth quarter worth $224,000. Finally, Rhumbline Advisers raised its holdings in Zevra Therapeutics by 18.4% in the fourth quarter. Rhumbline Advisers now owns 68,053 shares of the company’s stock worth $568,000 after purchasing an additional 10,573 shares in the last quarter. Hedge funds and other institutional investors own 35.03% of the company’s stock.

Zevra Therapeutics Trading Up 2.7%

NASDAQ:ZVRA opened at $8.66 on Monday. The stock has a market cap of $473.52 million, a price-to-earnings ratio of -4.40 and a beta of 1.87. The company has a quick ratio of 2.88, a current ratio of 2.88 and a debt-to-equity ratio of 0.84. The company’s 50 day moving average price is $7.54 and its 200-day moving average price is $8.07. Zevra Therapeutics, Inc. has a 52 week low of $4.20 and a 52 week high of $9.76.

Zevra Therapeutics (NASDAQ:ZVRA) last released its quarterly earnings data on Tuesday, May 13th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.15. The business had revenue of $20.40 million for the quarter, compared to analysts’ expectations of $16.96 million. Zevra Therapeutics had a negative return on equity of 159.54% and a negative net margin of 342.63%. During the same period in the prior year, the firm posted ($0.40) EPS. On average, equities research analysts forecast that Zevra Therapeutics, Inc. will post -1.95 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

ZVRA has been the topic of a number of research reports. JMP Securities set a $18.00 target price on shares of Zevra Therapeutics in a report on Wednesday, March 12th. Citigroup reaffirmed an “outperform” rating on shares of Zevra Therapeutics in a research note on Wednesday. HC Wainwright reissued a “buy” rating and issued a $20.00 price target on shares of Zevra Therapeutics in a research report on Thursday, March 13th. Canaccord Genuity Group raised their price objective on Zevra Therapeutics from $23.00 to $25.00 and gave the company a “buy” rating in a research report on Thursday, March 13th. Finally, Guggenheim boosted their target price on Zevra Therapeutics from $20.00 to $22.00 and gave the stock a “buy” rating in a report on Thursday, March 13th. Eight research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $22.29.

Insider Transactions at Zevra Therapeutics

In other Zevra Therapeutics news, Director John B. Bode acquired 10,000 shares of Zevra Therapeutics stock in a transaction that occurred on Wednesday, March 19th. The stock was bought at an average cost of $7.96 per share, for a total transaction of $79,600.00. Following the acquisition, the director now owns 40,000 shares of the company’s stock, valued at $318,400. This represents a 33.33% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Company insiders own 2.40% of the company’s stock.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.